Results 91 to 100 of about 12,338 (219)

Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma

, 2020
Objectives: Venetoclax, an orally available BCL2‐selective inhibitor, has demonstrated promising single‐agent anti‐tumour activity in myeloma especially patients with t(11;14).
Chim, CS, Wong, KY
core   +1 more source

Bortezomib-induced polyneuropathy

, 2013
Background: Peripheral neuropathy is a frequent side effect of bortezomib chemotherapy. Relatively little is known about the clinical characteristics of this neuropathy, especially with respect to pain.
Boer, Marjan, Rampen, Anneke, Sonneveld, Pieter, van den Bent, Martin; id_orcid, Heuvel, I, Jongen, Joost   +5 more
core   +1 more source

Apoptotic induction of bortezomib.

, 2016
A,C) Bortezomib treated chondrosarcoma cells showed a significantly higher level of caspase 3/7 activity than untreated cells. Untreated control cells served as reference value (ratio = 1). B,D) Cleavage of caspase-3 was detected after 24 h of bortezomib
Nicole Stuendl (310419), Andreas Leithner (310423), Heike Kaltenegger (422411), Beate Rinner (310418), Bibiane Steinecker-Frohnwieser (422412), Birgit Lohberger (310417)   +5 more
core   +1 more source

Bortezomib for the treatment of multiple myeloma [PDF]

, 2016
BACKGROUND: Multiple myeloma is a malignancy of plasma cells accounting for approximately 1% of cancers and 12% of haematological malignancies. The first-in-class proteasome inhibitor, bortezomib, is commonly used to treat newly diagnosed as well as ...
Wheatley, Keith, Andrea Will, Coyne, Imelda, Keith Wheatley, Hayden, Patrick J, Scott, Kathleen, Will, Andrea, Patrick J Hayden, Kathleen Scott, Imelda Coyne   +9 more
core   +1 more source

Spatial sequestration of activated-caspase 3 in aggresomes mediates resistance of neuroblastoma cell to bortezomib treatment

Scientific Reports
Neuroblastoma (NB) is the most common pediatric tumor and is currently treated by several types of therapies including chemotherapies, such as bortezomib treatment.
Kévin Berthenet, Eliézer Aïmontché, Sara El Mrini, Johan Brière, Nathalie Pion, Isabelle Iacono, Stéphanie Brejon, Karine Monier, Frédéric Catez, Gabriel Ichim, Valérie Combaret, Hichem C. Mertani, Jean-Jacques Diaz, Marie Alexandra Albaret   +13 more
doaj   +1 more source

Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma

Frontiers in Oncology, 2019
Multiple myeloma (MM) drug resistance highlights a need for alternative therapeutic strategies. In this study, we show that CASIN, a selective inhibitor of cell division cycle 42 (Cdc42) GTPase, inhibited proliferation and survival of melphalan ...
Phuong Nguyen, Phuong Nguyen, Jayati Chakrabarti, Jayati Chakrabarti, Yuan Li, Yuan Li, Khalid W. Kalim, Khalid W. Kalim, Mengnan Zhang, Lin Zhang, Yi Zheng, Yi Zheng, Fukun Guo, Fukun Guo   +13 more
doaj   +1 more source

Cesni‐cel (ARI0002h) in ultra‐high‐risk multiple myeloma with plasma cell leukaemia or central nervous system involvement

British Journal of Haematology, EarlyView.
ARI0002h induced response in 15/17 patients with plasma cell leukaemia (PCL)/central nervous system (CNS)‐multiple myeloma (MM) (87% achieved ≥ very good partial response [VGPR]) with a median progression‐free survival (PFS)/overall survival (OS) of 10.5 and 15.9 months respectively.
Carlos Jimenez‐Mira, Natalia Tovar, Núria Martínez‐Cibrián, Verónica González‐Calle, Nil Albiol, Nieves López‐Muñoz, Aina Oliver‐Caldés, Azucena González, José Miguel Mateos, Marta Español‐Rego, Laura Rosiñol, Manel Juan, Paola Charry, José María Sanchez‐Pina, Sergio Navarro, Daniel Munárriz, Lucía López‐Corral, Valentín Ortiz‐Maldonado, Sara Varea, Eulalia Olesti, Julio Delgado, Álvaro Urbano‐Ispizua, Joaquín Martínez‐López, María Victoria Mateos, Luis Gerardo Rodríguez‐Lobato, Carlos Fernández de Larrea   +25 more
wiley   +1 more source

Update on the optimal use of bortezomib in the treatment of multiple myeloma

, 2017
Meera Mohan, Aasiya Matin, Faith E Davies Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA Abstract: The proteasome inhibitor (PI) “bortezomib” has now been in routine clinical practice for ...
Mohan M, Davies FE, Matin A
core  

Bortezomib in multiple myeloma

, 2012
Multiple myeloma (MM) remains an incurable disease, and novel agents are therefore needed to improve outcome. Bortezomib is the first proteasome inhibitor to be approved by the US Food and Drug Administration and the European Agency for the Evaluation of
San Miguel, Jesús F., Mateos, Maria Victoria   +1 more
core   +1 more source

Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.

PLoS ONE, 2013
CK2 is a pivotal pro-survival protein kinase in multiple myeloma that may likely impinge on bortezomib-regulated cellular pathways. In the present study, we investigated CK2 expression in multiple myeloma and mantle cell lymphoma, two bortezomib ...
Sabrina Manni, Alessandra Brancalion, Elisa Mandato, Laura Quotti Tubi, Anna Colpo, Marco Pizzi, Rocco Cappellesso, Fortunato Zaffino, Speranza Antonia Di Maggio, Anna Cabrelle, Filippo Marino, Renato Zambello, Livio Trentin, Fausto Adami, Carmela Gurrieri, Gianpietro Semenzato, Francesco Piazza   +16 more
doaj   +1 more source